Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST)

  • Sarcomas (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Imatinib was proven to be effective for the adjuvant treatment of localized, surgically excised, gastrointestinal stromal tumors (GIST). Currently, there is proof that it is able to delay relapse and prolong survival. An effect on cure rate of localized GIST is still to be proven, given the shape of relapse-free survival curves, which apparently tend to overlap after 2-3 years from completion of the adjuvant period. Although observation for a longer follow-up is needed, attempts to prolong adjuvant therapy beyond the currently standard 3 years have been made and the results are awaited. However, the impact of more prolonged adjuvant intervals on secondary resistance is unknown, so that standard practice is still 3 years in most institutions. The adjuvant choice should be based on a rather precise identification of the relapse risk of the single patient, reserving treatment to the high-risk subgroups. The choice also should be personalized on the basis of genotype: generally, PDGFRA D842V mutated and wild-type GIST are excluded. Additional results from completed trials on a longer follow-up are awaited to further refine such “precision” decision-making. There are several instances in which part of the “adjuvant” treatment may be administered preoperatively, even on the face of a surgically resectable GIST, to make surgery more limited and/or safer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:• Of importance•• Of major importance

  1. Blanke CD, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–5.

    Article  PubMed  CAS  Google Scholar 

  2. Verweij J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–34.

    Article  PubMed  CAS  Google Scholar 

  3. Blanke CD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626–32.

    Article  PubMed  CAS  Google Scholar 

  4. Dematteo RP, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112(3):608–15.

    Article  PubMed  Google Scholar 

  5. Von Mehren M, et al. Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT + gastrointestinal stromal tumors (GIST). J Clin Oncol. 2011;29(Suppl):10016.

    Google Scholar 

  6. Van Glabbeke M, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23(24):5795–804.

    Article  PubMed  Google Scholar 

  7. Blesius A, et al. Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol. 2011;29(Suppl):10048.

    Google Scholar 

  8. DeMatteo RP, et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104. The ACOSOG Z9001 was the first randomized trial to demonstrate a benefit for adjuvant therapy with imatinib. The convincing benefit was in terms of relapse-free survival, the primary end point of this study, given the current favorable prognosis of advanced GIST patients.

    Article  PubMed  CAS  Google Scholar 

  9. Joensuu H, et al. One vs. three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72. The SSG XVIII/AIO trial demonstrated a RFS benefit in favor of 3 years of adjuvant therapy in comparison to one year (tested in ACOSOG Z9001 trial). Even more importantly in a sense was the demonstration that this translated also in an OS improvement, thus proving that adjuvant targeted therapy is able to provide a survival benefit.

    Article  PubMed  CAS  Google Scholar 

  10. Le Cesne A, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. The Lancet Oncology. 2010;11(10):942–9. This trial randomized patients between continuing therapy and stopping it after 1, 3, and 5 years in the metastatic setting, and demonstrated that targeted therapy needs to be maintained indefinitely.

    Article  PubMed  Google Scholar 

  11. Domont J, et al. Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol. 2011;29(Suppl):10054.

    Google Scholar 

  12. Demetri GD, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.

    Article  PubMed  CAS  Google Scholar 

  13. Reichardt P, et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment—the first analysis in the SSGXVIII/AIO trial patient population. ECCO-ESMO 2011 (Abstr 31LBA).

  14. Miettinen M, et al. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.

    Article  PubMed  Google Scholar 

  15. Joensuu H, et al. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.

    Article  PubMed  Google Scholar 

  16. Gold JS, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. The Lancet Oncology. 2009;10(11):1045–52. A nomogram is provided to predict RFS after resection of localized primary GIST, based on tumor size, location, and mitotic index.

    Article  PubMed  Google Scholar 

  17. Rossi S, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol. 2011;35(11):1646–56. A retrospective analysis concerning the natural history of GIST developed a prognostic nomogram for survival that considers site, size, and mitotic index. The latter is shown to be a continuous variable, thus suggesting the opportunity to develop prognosticators for relapse-free survival exploiting the mitotic index as a continuous rather than a dichotomous variable.

    Article  PubMed  Google Scholar 

  18. Hohenberger P, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg. 2010;97(12):1854–9. This study demonstrated that primary GIST patients with tumour rupture before or during resection have an exceedingly high risk of recurrence. These patients are clearly candidates for targeted therapy, whether it is conceived as an adjuvant or as therapy for already spread disease.

    Article  PubMed  CAS  Google Scholar 

  19. Rutkowski P, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes. Eur J Surg Oncol. 2011;37(10):890–6.

    Article  PubMed  CAS  Google Scholar 

  20. Heinrich MC, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342–9.

    Article  PubMed  CAS  Google Scholar 

  21. Martin-Broto J, et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol. 2010;21(7):1552–7.

    Article  PubMed  CAS  Google Scholar 

  22. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7):1247–53. This pooled analysis of data from the two randomized trials (EORTC62005 and ECOGS0033), comparing two doses of imatinib (400 vs. 800 mg daily) in patients with advanced GIST confirms a PFS advantage of high-dose imatinib among patients with KIT exon 9 mutations.

    Article  Google Scholar 

  23. Corless CL, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357–64.

    Article  PubMed  CAS  Google Scholar 

  24. Lasota J, et al. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245–66.

    Article  PubMed  CAS  Google Scholar 

  25. Emile JF, et al. Frequencies of KIT and PDGFRAmutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011; Sep 28 [Epub ahead of print]. This population-based series shows that the frequency of PDGFRA mutations (including the insensitive mutation PDGFRA D842V) in the localized setting is higher than observed in advanced series (given its better prognosis, although in the face of its insensitivity to targeted therapy).

  26. Carney JA, et al. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet. 2002;108(2):132–9.

    Article  PubMed  Google Scholar 

  27. Miettinen M, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30(1):90–6.

    Article  PubMed  Google Scholar 

  28. Mussi C, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res. 2008;14(14):4550–5.

    Article  PubMed  CAS  Google Scholar 

  29. Miettinen M, et al. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol. 2005;29(10):1373–81.

    Article  PubMed  Google Scholar 

  30. Agaram P, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008;14(10):3204–15.

    Article  PubMed  CAS  Google Scholar 

  31. Fiore M, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumours (GIST). Eur J Sur Oncol. 2009;35(7):739–45.

    Article  CAS  Google Scholar 

  32. Wang D, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann Surg Oncol. 2011; Mar 7 [Epub ahead of print].

  33. Gronchi A, et al. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol. 2011; [Epub ahead of print] doi:10.1245/s10434-011-2191-4.

  34. Choi H, et al. Response evaluation of gastrointestinal stromal tumors. Oncologist. 2008;13(2):4–7.

    Article  PubMed  Google Scholar 

  35. Van den Abbeele AD, et al. The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13(2):8–13.

    Article  PubMed  Google Scholar 

  36. Haller F, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007;14(2):526–32.

    Article  PubMed  Google Scholar 

Download references

Disclosures

P.G. Casali: honoraria from, consultant to, and had travel/accommodations expenses covered or reimbursed from Novartis, Pfizer, and Bayer; E. Fumagalli: honoraria from Novartis; A. Gronchi: honoraria, consultant to, and had travel/accommodations expenses covered or reimbursed from Novartis.

Author information

Authors and Affiliations

  1. Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Via G. Venezian 1, 20133, Milano, Italy

    Paolo G. Casali MD & Elena Fumagalli MD

  2. Sarcoma Surgery Unit, Istituto Nazionale Tumori, Milano, Italy

    Alessandro Gronchi MD

Authors
  1. Paolo G. Casali MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Fumagalli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Gronchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo G. Casali MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casali, P.G., Fumagalli, E. & Gronchi, A. Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). Curr. Treat. Options in Oncol. 13, 277–284 (2012). https://doi.org/10.1007/s11864-012-0198-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0198-0

Keywords

Search

Navigation